Mirae Asset Global ETFs Holdings
ALLO icon

Mirae Asset Global ETFs Holdings’s Allogene Therapeutics ALLO Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$222K Buy
92,886
+21,435
+30% +$43K ﹤0.01% 2307
2025
Q4 		$97.9K Sell
71,451
-93,329
-57% -$123K ﹤0.01% 2689
2025
Q3 		$204K Sell
164,780
-14,796
-8% -$17.6K ﹤0.01% 2308
2025
Q2 		$203K Sell
179,576
-106,457
-37% -$141K ﹤0.01% 2275
2025
Q1 		$418K Sell
286,033
-19,862
-6% -$37.4K ﹤0.01% 1961
2024
Q4 		$651K Buy
305,895
+58,331
+24% +$144K ﹤0.01% 1778
2024
Q3 		$695K Sell
247,564
-16,765
-6% -$44.7K ﹤0.01% 1744
2024
Q2 		$618K Buy
+264,329
New +$780K ﹤0.01% 1718

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's ALLO Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings increased its Allogene Therapeutics (ALLO) stake by 30% in Q1 2026, buying an estimated $43K and bringing the position to 92,886 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #2307.

Mirae Asset Global ETFs Holdings first reported a position in ALLO in Q2 2024 and has held it in 8 quarters since. The position peaked at $695K in Q3 2024. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Mirae Asset Global ETFs Holdings held 92,886 shares of Allogene Therapeutics worth $222K as of Q1 2026.
  • Mirae Asset Global ETFs Holdings bought 21,435 Allogene Therapeutics shares in Q1 2026, an estimated $43K.
  • Allogene Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #2307 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Allogene Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Mirae Asset Global ETFs Holdings's Allogene Therapeutics position peaked at $695K in Q3 2024.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.